Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cipla
Boehringer Ingelheim
Chinese Patent Office
Farmers Insurance
Baxter
Dow
Mallinckrodt
Argus Health
Cerilliant

Generated: December 11, 2017

DrugPatentWatch Database Preview

DUEXIS Drug Profile

« Back to Dashboard

Which patents cover Duexis, and what generic alternatives are available?

Duexis is a drug marketed by Horizon Pharma and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-four patent family members in fourteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Horizon PharmaDUEXISfamotidine; ibuprofenTABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Horizon PharmaDUEXISfamotidine; ibuprofenTABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Horizon PharmaDUEXISfamotidine; ibuprofenTABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Horizon PharmaDUEXISfamotidine; ibuprofenTABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Horizon PharmaDUEXISfamotidine; ibuprofenTABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Horizon PharmaDUEXISfamotidine; ibuprofenTABLET;ORAL022519-001Apr 23, 2011RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for DUEXIS

Drugname Dosage Strength RLD Submissiondate
ibuprofen and famotidineTablets800 mg/26.6 mgDuexis12/6/2011

International Patent Family for Tradename: DUEXIS

Country Document Number Estimated Expiration
New Zealand574200► Subscribe
European Patent Office2043637► Subscribe
Austria539747► Subscribe
Japan2009543885► Subscribe
China101257800► Subscribe
Israel196425► Subscribe
Portugal2043637► Subscribe
New Zealand565846► Subscribe
European Patent Office1919288► Subscribe
China101516368► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Queensland Health
Novartis
Chubb
Daiichi Sankyo
Johnson and Johnson
UBS
Cantor Fitzgerald
Teva
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot